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Abstract
Background:  Computed Tomography Cholangiography (CTC) is a fast and widely available
alternative technique to visualise hepatobiliary disease in patients with an inconclusive ultrasound
when MRI cannot be performed. The method has previously been relatively unknown and sparsely
used, due to concerns about adverse reactions and about image quality in patients with impaired
hepatic function and thus reduced contrast excretion. In this retrospective study, the feasibility and
the frequency of adverse reactions of CTC when using a drip infusion scheme based on bilirubin
levels were evaluated.
Methods: The medical records of patients who had undergone upper abdominal spiral CT with
subsequent three-dimensional rendering of the biliary tract by means of CTC during seven years
were retrospectively reviewed regarding serum bilirubin concentration, adverse reaction and
presence of visible contrast media in the bile ducts at CT examination. In total, 153 consecutive
examinations in 142 patients were reviewed.
Results: Contrast media was observed in the bile ducts at 144 examinations. In 110 examinations,
the infusion time had been recorded in the medical records. Among these, 42 examinations had an
elevated bilirubin value (>19 umol/L). There were nine patients without contrast excretion; 3 of
which had a normal bilirubin value and 6 had an elevated value (25–133 umol/L). Two of the 153
examinations were inconclusive. One subject (0.7%) experienced a minor adverse reaction – a
pricking sensation in the face. No other adverse effects were noted.
Conclusion: We conclude that drip infusion CTC with an infusion rate of the biliary contrast
agent iotroxate governed by the serum bilirubin value is a feasible and safe alternative to MRC in
patients with and without impaired biliary excretion.
In this retrospective study the feasibility and the frequency of adverse reactions when using a drip 
infusion scheme based on bilirubin levels has been evaluated.
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Background
For diagnosis of hepatobiliary disease, ultrasound and MR
cholangiography (MRC) are most frequently used. Endo-
scopic Retrograde Cholangiography (ERC) is often
regarded as the gold standard for visualising biliary dis-
ease. The latter modality is invasive, user-dependent and
may induce pancreatitis. It should therefore not be per-
formed in patients where intervention is less certain.
Ultrasound, on the other hand, is easily tolerated by the
patients and cost effective. The modality is, however, user-
dependent and the captured images are not easily under-
stood by clinicians. MRC is superior in visualising the bil-
iary system, and the images are appreciated by the
surgeons at surgical planning. It does not require any con-
trast agent to visualise the bile ducts, and dilatation and
gallstones in the common bile duct are easily detected [1-
3]. Unfortunately, MRC cannot be performed in all
patients and hospitals due to limited availability of MRI
or due to contraindications. MRC is also often inconclu-
sive in patients with air in the biliary system, e.g. after pap-
illotomy or liver surgery with entero-hepatic anastomoses
(such as Whipple's operation and Billroth 2). Surgical
clips after cholecystectomy may also give artefacts mim-
icking a ductal cancer or a stone [4,5]. An alternative non-
invasive method to ultrasound and MRC is therefore
required.
Computed Tomography Cholangiography (CTC) is a fast
and widely available technique to visualise hepatobiliary
disease. Without contrast administration, multi detector
CT has been reported to have a sensitivity of 65%–88%
and a specificity of 84%–97% to detect gallstones [6,7].
Techniques to improve the sensitivity and specificity by
administering biliary contrast media orally [8] or intrave-
nously [9,10] have been developed, but are not wide-
spread. Possible explanations for infrequent use of CTC
might be the low resolution of single detector helical CT
and reports of an unacceptable high number of adverse
events after injection of meglumine iotroxate [11]. With
the development of multidetector CT, the resolution of
CTC exceeds that of MR. The number of adverse reactions
with biliary contrast media has probably diminished by
infusing the contrast media instead of injecting.
The aim of this retrospective study was to evaluate pro-
longed drip infusion CT cholangiography (CTC) in
patients with suspected obstructive biliary disease with
respect to both feasibility and rate of adverse reactions
after administration of the biliary contrast agent (iotrox-
ate).
Methods
This is a retrospective study in 142 consecutive patients
(68 men and 74 women, mean age 69 years, range 24 – 95
years) referred for investigation of biliary disease during
the period from January 1996 to January 2003. After
approval by the ethics committee for the region, the med-
ical records of all patients were retrospectively reviewed
regarding bilirubin level, infusion time and adverse
events. Adverse events were defined as any signs of reac-
tion to contrast media that occurred after the injection,
such as anaphylaxis, urticaria and respiratory distress.
Administration of contrast media
The serum bilirubin concentration was measured before CT
examination using standard clinical laboratory methods
used at the hospital. 100 ml of meglumine iotroxate (Bili-
scopin®, Schering AG, Berlin, Germany) 50 mg I/ml was
administered by intravenous drip infusion. In order to
allow longer infusion times, the solution volume was
increased by dilution with isotonic sodium chloride (500
ml). The infusion time was determined by the measured
bilirubin level according to a schematic protocol (Table 1).
Following the guidelines from the manufacturer, the drip
infusion was started at a low infusion rate (0.5 ml/min)
and increased to the desired infusion rate during the fol-
lowing 3–5 minutes. The CT scan was started immediately
after the infusion was completed. For distension of the dis-
tal duodenum, the patients ingested two glasses of drinking
water immediately before the CT examination. To evaluate
Table 2: CT acquisition parameters
Type of scanner Collimation Pitch Increment mAs kV Number of 
examinations
Single Slice 1 × 5.0 mm 1.5 1 mm 200 120 103
Multi-slice 4 × 2.5 mm 6 1 mm 130 120 46
Multi-slice 16 × 0.75 mm varying 0.5 mm 130 120 4
Table 1: The infusion rate of iotroxate (Biliscopin®) was governed 
by the bilirubin level prior to the investigation. The same total 
amount of Iodine (5 g) was given to all patients.
Serum bilirubin Infusion time
<20 µmol/ml 40–60 min
21–40 µmol/ml 1–3 hours
41–99 µmol/ml 3–4 hours
>100 µmol/ml 5 hoursBMC Medical Imaging 2006, 6:1 http://www.biomedcentral.com/1471-2342/6/1
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compliance to the protocol, the medical records were
reviewed regarding the given infusion time at the ward.
Scanning parameters
Patients were scanned in the right oblique position by
means of thin-section single-breath-hold helical CT in the
cranio-caudal direction. Specific scan protocols varied
depending on the CT scanner available at the time of
examination (Table 2). Between December 1995 and
November 1999, 102 patients were scanned with a single-
slice CT scanner (Somatom A; Siemens Medical Systems,
Forcheim, Germany). From December 1999 to November
2002, a 4-slice multi-detector CT scanner (Somatom Vol-
ume Zoom; Siemens Medical Systems, Forcheim, Ger-
many) was used in 44 exams. Between December 2002
and January 2003, a 16-slice multi-detector CT scanner
(Somatom Sensation16; Siemens Medical Systems,
Forcheim, Germany) was used in 6 exams.
Evaluation of contrast media excretion
The attenuation in choledochus and liver was obtained
retrospectively by measurement in the restored digital
images in all examinations with bilirubin >19 µmol/L (n
= 42), as well as in 67 individuals also described in
another study [12], 19 of the latter with bilirubin >19
µmol/L. In total, attenuation values from 90 (= 42 + 67 -
19) patients were obtained.
Review of literature
A MEDLINE search was performed for all clinical studies
in English published during the period 1975–2004 con-
cerning iotroxate, using the words "Biliscopin" or "iotrox-
ate". All articles were reviewed for reports regarding
adverse events. The pooled frequency of adverse events
was calculated for all articles with a number of patients
>100 where the contrast had been infused for 30 minutes
or more.
Statistical methods
Data are given as mean (± standard deviation). Frequen-
cies are given with their 95% confidence interval, com-
puted with normal approximation.
Results
Out of 153 examinations performed in 142 patients, one
subject experienced a minor reaction (pricking sensation
in the face) following the administration of 70 ml of con-
trast. In this patient, the pre-exam bilirubin value was nor-
mal (11 µmol/L) and the planned infusion time was 60
minutes. Four weeks later, the same patient successfully
underwent a repeated CT cholangiography using the same
infusion rate without any adverse reactions. In the other
141 patients (151 examinations), no adverse reaction was
noted in the medical records. Thus, the observed fre-
quency of adverse reactions in this material was 1/153
(0.65%). Of the 153 examinations, 10 were performed in
out-patients. These patients normally stay in the radiology
department one hour after the contrast injection has been
completed. Due to the retrospective nature of this study,
late mild adverse advents may not have been recorded in
these 10 patients. More severe adverse reactions such as a
skin rash, itches, etc. are, however, usually reported to the
hospital by the patients and according to the routines of
the hospital, adverse reactions are always noted in the
medical records after an X-ray examination. The hospital
is the only one in the district and no notes could be found
about adverse advents in the patients' files (files from
departments of radiology, surgery and internal medicine
were reviewed).
The mean bilirubin value was 20 (± 25) µmol/L. 42
patients had an elevated bilirubin value (defined as >19
µmol/L). Information regarding the infusion time used at
the ward had been noted in the medical records in 110 out
of 153 examinations. The mean infusion time was 82 (±
Table 3: The bilirubin value, infusion time and final diagnosis in the nine cases where no secretion of contrast media was observed at 
DIC-CT.
Bilirubin value, µmol/L Infusion time, minutes Reported findings in medical records, final diagnosis Reported findings at DIC-CT
133 120 Hepatitis Type B1 wide bile duct
120 240 Pancreatitis 1,2 inconclusive
79 180 Intraductal stone in choledochus and pancreatitis 7,2,6 Intraductal stone
73 120 Cholecystitis1,2 wide bile duct
30 unknown Concrememt in choledochus1,2,3,6, Intraductal stone
25 unknown Concrement in choledochus, Total occlusion and Klatskin 
tumour5,7
Intraductal stone, tumour
16 60 Distal stenosis in choledochus and pancreatitis 4,5,7 inconclusive
12 60 Total occlusion in choledochus, pancreas tumour 2,3 wide bile duct
8 60 Post operative cholangitis/cholecystitis with bile fistula and 
leakage1,6,7
fluid-filled cavity
The method by which the final diagnosis was made is indicated by the superscript numbers where 1 = laboratory findings, 2 = ultrasound, 3 = 
ultrasound with fine needle biopsy, 4 = MRCP, 5 = operation, 6 = ERCP and 7 = PTC.BMC Medical Imaging 2006, 6:1 http://www.biomedcentral.com/1471-2342/6/1
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42) minutes. Disregarding potential measurement errors of
Attenuation in choledochus and liver at DIC-CT as a function of serum bilirubin before the examination Figure 2
Attenuation in choledochus and liver at DIC-CT as a function of serum bilirubin before the examination.
The infusion time of iotroxate (Biliscopin®) in relation to bilirubin level prior to the investigation Figure 1
The infusion time of iotroxate (Biliscopin®) in relation to bilirubin level prior to the investigation. The recommended infusion 
times were followed in 103 out of the 110 cases (94%) where information on infusion time was found in the medical records. 
Cases in which the recommendations were not followed are encircled (n = 7). Unfortunately, none of the three (3/110) exam-
inations with a bilirubin value >100 µmol/ml was performed according to the infusion scheme. The patient with the highest 
bilirubin value (159 µmol/ml) had good diagnostic excretion of contrast in the bile ducts, whereas the other two had no excre-
tion.BMC Medical Imaging 2006, 6:1 http://www.biomedcentral.com/1471-2342/6/1
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at most 2 µmol/L, seven infusions (5%) had not been per-
formed according to the protocol. Five of these received the
infusion too fast and 2 too slow (Fig. 1). All three patients
with a bilirubin >100 µmol/L were among the seven
patients who did not receive the correct infusion rate. The
intended infusion rate (5 hours) could therefore not be
evaluated.
Excretion of contrast media was observed in 93% (143/
153) of all exams (one examination aborted due to poten-
tial contrast reaction). In patients with elevated serum
bilirubin (>19 µmol/L) contrast media in the bile was
observed in 36 out of 42 patients (86%). No visible secre-
tion of contrast was reported in 9 patients (Table 3). In
three of these, the infusion protocol had not been fol-
lowed, with too fast infusion (bilirubin 73–133 µmol/L).
The final diagnoses in the patients with no visible secre-
tion are also shown in Table 3. Three of these had occlu-
sive intraductal stones, all of which were reported at the
CTC. Two patients had a malignancy affecting the bile
ducts. One of these was reported at CTC and the other
showed signs of dilated bile ducts.
The remaining 4 patients had hepatitis, pancreatitis,
cholangitis or cholecystitis.
The observed attenuation in choledochus and liver for dif-
ferent serum bilirubin levels is shown in Fig. 2.
Review of literature
In total, 42 original publications in English were found.
Those with more than 100 patients and with an infusion
time of 30 minutes or more are listed in Table 4 as well as
the pooled number of adverse events (2.27%).
Discussion
When the bile ducts are obstructed, excretion of bile and
contrast media is decreased. It has therefore been assumed
that CT cholangiography cannot be performed in patients
with elevated serum bilirubin concentration [9,10]. In this
study, the infusion rate of the contrast media was adjusted to
the bilirubin value (Table 1). The aim was to keep the con-
centration within the excretory capacity of the hepatocytes in
order to optimise the concentration in bile. By using this
scheme, contrast excretion into the bile ducts was observed
in 93% of all exams. In patients with elevated serum
bilirubin (>19 µmol/L), contrast media in the bile was
observed in 86%. Excretion of contrast media was noted
even when the bilirubin concentration was as high as 159
µmol/L (Fig. 3, 4). It has previously been recommended not
to perform CTC in patients with bilirubin >50 µmol/L (3
mg/dL) [14]. In this study, excretion was observed in four
out of eight patients with bilirubin >50 µmol/L. In three of
those without contrast excretion, however, the infusion pro-
tocol had not been followed (too fast infusion). Although
absence of contrast media in the bile ducts is more likely in
patients with greatly elevated bilirubin, CTC is not useless in
these patients – only two of the nine examinations without
contrast excretion were inconclusive. In the other seven
cases, CTC findings could guide the referring physician to
other examinations and the final diagnosis (Table 3).
The lack of excretion may also constitute valuable infor-
mation. Patients without excretion are likely to have
either a total occlusion of the main bile duct/choledochus
Table 4: Published studies on the frequency of adverse reactions at infusion of iotroxate at intravenous cholangiography. Included are 
all studies with at least 100 patients using an infusion time of at least 30 min. The severity of the reactions is graded as reported. The 
number in superscript denotes the corresponding reference.
No. of Patients Total Minor Intermediate Severe Fatal
Nilsson 198711 1 446 49 (3.4%) 41 (2.9%) 5 (0.35%) 3 (0.21%) 0
Daly 198731 286 4 (1.4%) 4 (1.4%) 0 0 0
Joyce 199132 100 2 (2.0%) 2 (2.0%) 0 0 0
Wigmore 199333 1 0 0 00000
Patel 199334 113 3 (2.7%) 3 (2.7%) 0 0 0
Grunshaw 199335 137 4 (2.9%) 3 (2.2%) 1 (0.7%) 0 0
ASacharias 199536 1 061 11 (1.0%) 11 A (1.0%) 0 0
Kwon 199816 440 2 (0.5%) 2 (0.5%) 0 0 0
Kitami 200637 220 3 (1.4%) 3 (1.5%) 0 0 0
Okada 200517 432 4 (0.9% 4 (0.9%) 0 0 0
Hirao 200022 120 2 (1.7%) 2 (1.7%) 0 0 0
BTakamatsu 200438 132 1 (0.8%) 1 (0.8%) 0 0 0
Total 4587 85 65 17 3 0
Frequency (95% 
confidence limits)
1.9% (1.5%–2.2%) 1.4% (1.1%–1.8% 0.4% (0.2%–0.5%) 0.1% (0–0.1%) 0
ANo difference was made between minor and intermediate adverse events.
B The infusion time was 25–30 min. The number of complications in the article was reported by personal communication.BMC Medical Imaging 2006, 6:1 http://www.biomedcentral.com/1471-2342/6/1
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or severely impaired hepatocyte function. The bilirubin
concentration, if not already considerably elevated, is
likely to increase in these patients. In this study, the lack
of excretion could be explained by the final diagnosis in
all patients (Table 3).
The protein-binding characteristics essential for biliary
contrast media increase the risk of adverse reactions
[11,15]. In a previously published review of the literature
on the frequency of adverse reactions in examinations
with short injection time (<10 min), the pooled number
of adverse events was three times higher (16% vs. 5%)
than after infusion (>30 min) of the same amount of con-
trast media [11]. The frequency of adverse events of
iotroxate (Biliscopin®) at infusion has been reported to be
as high as 3.4%, with a pooled frequency of 1.9% (Table
4). It has been proposed that the tolerance of intravenous
biliary contrast media is improved when a slow infusion
technique is used (up to one hour of infusion) [16,17].
Our study supports this proposal, as there was only one
adverse reaction, which was mild, in 142 patients and 153
examinations (0.65%).
After an inconclusive ultrasound examination, MRC has the
advantage of not exposing the patient to radiation and con-
trast media. On the other hand, in many clinical situations
Traffic accident with a liver rupture and leakage from a small  bile duct Figure 5
Traffic accident with a liver rupture and leakage from a small 
bile duct. The DIC-CT examination led the surgeon correctly 
to the leaking bile duct (arrow). The diameter of the rup-
tured bile duct was 1 mm.
In spite of an elevated bilirubin value, a good contrast excre- tion can be observed when a prolonged infusion time is used Figure 3
In spite of an elevated bilirubin value, a good contrast excre-
tion can be observed when a prolonged infusion time is used. 
In this case, the bilirubin value was 78 µmol/L and the infu-
sion time was 3 hours. Final diagnosis was status post 
choledochoduodenostomy.
A vast number of biliary stones visualized in the choledochus  duct Figure 4
A vast number of biliary stones visualized in the choledochus 
duct. Pre-examination bilirubin was 29 µmol/L (infusion time 
not noted in the medical record). ERCP verified the bile duct 
stones.BMC Medical Imaging 2006, 6:1 http://www.biomedcentral.com/1471-2342/6/1
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the availability of MRI examinations with short notice is lim-
ited. The sensitivity and specificity of contrast enhanced CTC
to detect choledocholithiasis are comparable to those of
MRC (sensitivity 86–93% and 80–95%, respectively, and
specificity 94–100% and 88–96%, respectively) [3,8,18,19].
CTC is also faster than MRC, which may be of importance in
patients with difficulties in lying in the supine position for a
prolonged time or when evaluating severely ill patients.
CTC has been used to preoperatively evaluate aberrant
bile ducts before laparoscopic cholecystectomy. The fre-
quency of anatomic variants that may affect the outcome
of laparoscopic cholecystectomy was estimated to be 15%
with CTC [16,20,21]. In clinical practise, the frequency of
bile duct injuries is about 0.5–1.5% [22,23]. The potential
value of pre-operative mapping of the biliary system by
using CTC must therefore be weighed against the cost and
radiation.
With injection of contrast media via biliary drainage cath-
eters, CTC has been successfully used to visualize the
extent of ductal invasion by hilar carcinoma [24].
Whether administration of contrast media orally or intra-
venously may achieve similar results in patients without
drainage has not been shown.
In clinical practise, CTC has been reported to be the pre-
ferred modality to evaluate living donors prior to liver
transplantation [25]. The main reported advantage to MRI
and MRC was the superior mapping of the biliary tree [26]
– in other respects the two modalities were considered
equivalent for the planning [25]. After introduction of
CTC, the use of an intraoperative cholangiogram has been
reported to be significantly reduced at living donor liver
transplantation [27]. After liver surgery, there is a risk of
biliary leaks. In these patients, and in patients with trau-
matic rupture of the biliary tree, CTC may be useful to
demonstrate the leak (fig 5) [28]. Cholescintigraphy can
also demonstrate biliary leaks [29], but the resolution is
low compared to CT. To our knowledge, there is no other
non-invasive technique to visualise a leakage from the bil-
iary tree (unless a functioning external biliary drainage is
present, enabling a secondary cholangiography).
CTC has been shown to provide kinetic and functional
information [30]. This is also possible in contrast
enhanced MRC when hepatocyte specific contrast media
is used (Gd-BOPTA and Gd-EOB-BOPTA). Further studies
are required to evaluate whether contrast enhanced MRC
or CTC should be preferred to evaluate biliary kinetics.
The main disadvantages of CTC compared to MRC are the
use of radiation and contrast media. In our study, includ-
ing the literature review, the frequency and severity of
adverse reactions was low when infusing the contrast
media. The disadvantage of infusion is the need of super-
vision, which is impractical in a radiology department. In
our setting, this problem was solved by admitting the
patients to a ward for infusion prior to CTC.
Conclusion
This study indicates that drip infusion CTC with an infu-
sion rate of iotroxate governed by the serum bilirubin
concentration is a feasible and safe tool in patients with
and without impaired biliary excretion. In addition to
those with inconclusive MRC or contraindications, CTC is
a diagnostic alternative in patients already admitted to the
hospital for whom a reliable diagnosis or mapping of the
biliary tree is required within a limited time. In younger
patients, non-ionising methods (i.e. MRC or a repeated
ultrasound examination) should be preferred.
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